An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
NCT04842643
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Immunodeficiency Disease
Interventions
BIOLOGICAL:
IGSC 20% infusion
Sponsor
Takeda